Epizyme Inc (EPZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Epizyme Inc (EPZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH194377D
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc (EPZM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10

Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Epizyme Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Epizyme Enters into Partnership with US Oncology Research 12

Epizyme Enters into Agreement with Genentech 13

Strata Oncology Enters into Agreement with EpiZymev 14

Epizyme Enters into Research Agreement with National Cancer Institute 15

Epizyme Enters into Agreement with Foundation Medicine 16

Epizyme Enters into Agreement with Genentech 17

Epizyme Enters into Agreement with Lymphoma Study Association 18

Licensing Agreements 19

Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19

Equity Offering 21

Epizyme Raises USD86.2 Million in Public Offering of Shares 21

Epizyme Raises USD161 Million in Public Offering of Shares 23

EpiZyme Raises USD1.9 Million in Public Offering of Shares 25

Epizyme Raises USD138 Million in Public Offering of Shares 26

Epizyme Raises USD139 Million in Public Offering of Shares 28

EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For USD 107.5 Million 30

EpiZyme Completes IPO For USD 89 Million 32

Epizyme Inc-Key Competitors 34

Epizyme Inc-Key Employees 35

Epizyme Inc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Nov 02, 2018: Epizyme reports third quarter 2018 financial results and Tazemetostat progress 37

Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates 39

May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates 41

Mar 13, 2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results 43

Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 45

Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress 46

May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update 48

Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals 49

Corporate Communications 51

Jul 23, 2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer 51

Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors 52

Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization 53

Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company 54

Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors 55

Clinical Trials 56

Dec 11, 2017: Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Epizyme Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Epizyme Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10

Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Epizyme Enters into Partnership with US Oncology Research 12

Epizyme Enters into Agreement with Genentech 13

Strata Oncology Enters into Agreement with EpiZymev 14

Epizyme Enters into Research Agreement with National Cancer Institute 15

Epizyme Enters into Agreement with Foundation Medicine 16

Epizyme Enters into Agreement with Genentech 17

Epizyme Enters into Agreement with Lymphoma Study Association 18

Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19

Epizyme Raises USD86.2 Million in Public Offering of Shares 21

Epizyme Raises USD161 Million in Public Offering of Shares 23

EpiZyme Raises USD1.9 Million in Public Offering of Shares 25

Epizyme Raises USD138 Million in Public Offering of Shares 26

Epizyme Raises USD139 Million in Public Offering of Shares 28

EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For USD 107.5 Million 30

EpiZyme Completes IPO For USD 89 Million 32

Epizyme Inc, Key Competitors 34

Epizyme Inc, Key Employees 35

Epizyme Inc, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Epizyme Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17958
Site License
USD 500 INR 35915
Corporate User License
USD 750 INR 53873

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com